O
Orlando M. Gutiérrez
Researcher at University of Alabama at Birmingham
Publications - 232
Citations - 15613
Orlando M. Gutiérrez is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Kidney disease & Renal function. The author has an hindex of 48, co-authored 201 publications receiving 13353 citations. Previous affiliations of Orlando M. Gutiérrez include Harvard University & University of Alabama.
Papers
More filters
Journal ArticleDOI
FGF23 induces left ventricular hypertrophy
Christian Faul,Ansel P. Amaral,Behzad N. Oskouei,Ming Chang Hu,Alexis Sloan,Tamara Isakova,Orlando M. Gutiérrez,Robier Aguillon-Prada,Joy Lincoln,Joshua M. Hare,Peter Mundel,Azorides R. Morales,Julia J. Scialla,Michael J. Fischer,Michael J. Fischer,Elsayed Z. Soliman,Jing Chen,Alan S. Go,Sylvia E. Rosas,Lisa Nessel,Raymond R. Townsend,Harold I. Feldman,Martin St. John Sutton,Akinlolu O. Ojo,Crystal A. Gadegbeku,Giovana Seno Di Marco,Stefan Reuter,Dominik Kentrup,Klaus Tiemann,Marcus Brand,Joseph A. Hill,Orson W. Moe,Makoto Kuro-o,John W. Kusek,Martin G. Keane,Myles Wolf +35 more
TL;DR: It is reported that elevated FGF23 levels are independently associated with LVH in a large, racially diverse CKD cohort and suggested that chronically elevated F GF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD.
Journal ArticleDOI
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.
Orlando M. Gutiérrez,Michael Mannstadt,Tamara Isakova,Jose Alejandro Rauh-Hain,Hector Tamez,Anand Shah,Kelsey Smith,Hang Lee,Ravi Thadhani,Harald Jüppner,Myles Wolf,Myles Wolf +11 more
TL;DR: Increased FGF-23 levels appear to be independently associated with mortality among patients who are beginning hemodialysis treatment, and a potential biomarker that can be used to guide strategies for the management of phosphorus balance in patients with chronic kidney disease is investigated.
Journal ArticleDOI
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Tamara Isakova,Patricia Wahl,Gabriela Vargas,Orlando M. Gutiérrez,Julia J. Scialla,Huiliang Xie,Dina Appleby,Lisa Nessel,Keith Bellovich,Jing Chen,L. Lee Hamm,Crystal A. Gadegbeku,Edward Horwitz,Raymond R. Townsend,Cheryl A.M. Anderson,James P. Lash,Chi-yuan Hsu,Mary B. Leonard,Myles Wolf +18 more
TL;DR: Increased FGF23 is a common manifestation of CKD that develops earlier than increased phosphate or PTH, and may be a sensitive early biomarker of disordered phosphorus metabolism in patients with CKD and normal serum phosphate levels.
Journal ArticleDOI
Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients with Chronic Kidney Disease
Tamara Isakova,Huiliang Xie,Wei Yang,Dawei Xie,Amanda H. Anderson,Julia J. Scialla,Patricia Wahl,Orlando M. Gutiérrez,Susan Steigerwalt,Jiang He,Stanley Schwartz,Joan Lo,Akinlolu O. Ojo,James H. Sondheimer,Chi-yuan Hsu,James P. Lash,Mary B. Leonard,John W. Kusek,Harold I. Feldman,Myles Wolf +19 more
TL;DR: Elevated FGF-23 is an independent risk factor for end-stage renal disease in patients with relatively preserved kidney function and for mortality across the spectrum of chronic kidney disease.
Journal ArticleDOI
Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease
Orlando M. Gutiérrez,Tamara Isakova,Eugene P. Rhee,Anand Shah,Julie Holmes,Gina Collerone,Harald Jüppner,Myles Wolf +7 more
TL;DR: It is concluded that FGF-23 levels increase early in CKD before the development of serum mineral abnormalities and are independently associated with serum phosphate, Fe(PO4), and calcitriol deficiency.